Previous Close | 108.48 |
Open | 108.34 |
Bid | 109.00 x 90000 |
Ask | 109.10 x 90000 |
Day's Range | 108.28 - 108.34 |
52 Week Range | 91.00 - 125.75 |
Volume | |
Avg. Volume | 128 |
Market Cap | 189.622B |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | 23.34 |
EPS (TTM) | 4.64 |
Earnings Date | Oct 18, 2022 - Oct 24, 2022 |
Forward Dividend & Yield | 1.87 (1.72%) |
Ex-Dividend Date | Jul 14, 2022 |
1y Target Est | 132.05 |
Subscribe to Yahoo Finance Plus to view Fair Value for ABL.F
With 50 consecutive years of dividend growth, healthcare giant Abbott Laboratories (NYSE: ABT) is a Dividend King. In late July, Abbott Laboratories shared its financial results for the second quarter ended June 30. As was also the case in the previous quarter, Abbott's nutrition segment was the only segment to not log year-over-year sales growth.
Abbott Laboratories (NYSE: ABT) is investing €440 million in Ireland with plans for a major new manufacturing plant in Kilkenny and additional jobs in Donegal, state investment agency IDA Ireland said. The company plans to hire 1,000 people in Ireland, which has 5,000 staff in the country. Abbott will expand its manufacturing facilities in the northwest county of Donegal and build a new plant at the other end of the country in Kilkenny. Subject to planning permission, the new 250,000 sq. ft. man
Abbott, leading experts discuss how technology can transform the future of healthcare at Aspen Ideas: Health event.